Identification of novel determinants of resistance to lapatinib in ERBB2-amplified cancers (Q34615545)

3 August 2017

Identification of novel determinants of resistance to lapatinib in ERBB2-amplified cancers (English)

1 reference

3 August 2017

D Cunningham

7

0 references

Alan Ashworth

10

object named as

A Ashworth

1 reference

3 August 2017

9

C J Lord

1 reference

3 August 2017

5

A Mackay

1 reference

3 August 2017

D Wetterskog

1

1 reference

3 August 2017

K-K Shiu

2

1 reference

3 August 2017

I Chong

3

1 reference

3 August 2017

T Meijer

4

1 reference

3 August 2017

M Lambros

6

1 reference

3 August 2017

J S Reis-Filho

8

1 reference

3 August 2017

language of work or name

English

0 references

publication date

11 March 2013

1 reference

3 August 2017

1 reference

3 August 2017

33

1 reference

3 August 2017

8

1 reference

3 August 2017

966-976

1 reference

https://scigraph.springernature.com/pub.10.1038/onc.2013.41

3 August 2017

0 references

cites work

Gene expression profiling in breast cancer: classification, prognostication, and prediction

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.41

Emerging targeted therapies for breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.41

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.41

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.41

Human epidermal growth factor receptor 2 assessment in a case-control study: comparison of fluorescence in situ hybridization and quantitative reverse transcription polymerase chain reaction performed by central laboratories.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.41

Determining true HER2 gene status in breast cancers with polysomy by using alternative chromosome 17 reference genes: implications for anti-HER2 targeted therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.41

HER-2 testing in breast cancer using immunohistochemical analysis and fluorescence in situ hybridization: a single-institution experience of 2,279 cases and comparison of dual-color and single-color scoring

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.41

HER2 amplification ratios by fluorescence in situ hybridization and correlation with immunohistochemistry in a cohort of 6556 breast cancer tissues

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.41

Beyond trastuzumab: new treatment options for HER2-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.41

ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.41

A hierarchical network of interreceptor interactions determines signal transduction by Neu differentiation factor/neuregulin and epidermal growth factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.41

Single-chain antibody-mediated intracellular retention of ErbB-2 impairs Neu differentiation factor and epidermal growth factor signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.41

ErbB2 is necessary for induction of carcinoma cell invasion by ErbB family receptor tyrosine kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.41

Neu differentiation factor activation of ErbB-3 and ErbB-4 is cell specific and displays a differential requirement for ErbB-2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.41

Lapatinib plus capecitabine for HER2-positive advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.41

Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.41

Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.41

PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.41

Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.41

The therapeutic effect of anti-HER2/neu antibody depends on both innate and adaptive immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.41

Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.41

Understanding the mechanisms behind trastuzumab therapy for human epidermal growth factor receptor 2-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.41

Human breast cancer cells selected for resistance to trastuzumab in vivo overexpress epidermal growth factor receptor and ErbB ligands and remain dependent on the ErbB receptor network

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.41

Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.41

Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.41

PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.41

An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.41

A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.41

Phosphatidylinositol 3-kinase hyperactivation results in lapatinib resistance that is reversed by the mTOR/phosphatidylinositol 3-kinase inhibitor NVP-BEZ235.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.41

Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.41

Quantitation of p95HER2 in paraffin sections by using a p95-specific antibody and correlation with outcome in a cohort of trastuzumab-treated breast cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.41

Clinical benefit of lapatinib-based therapy in patients with human epidermal growth factor receptor 2-positive breast tumors coexpressing the truncated p95HER2 receptor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.41

Genomic and transcriptional aberrations linked to breast cancer pathophysiologies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.41

The genomic profile of HER2-amplified breast cancers: the influence of ER status

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.41

High-resolution genomic and expression analyses of copy number alterations in HER2-amplified breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.41

DNA amplifications in breast cancer: genotypic-phenotypic correlations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.41

A census of amplified and overexpressed human cancer genes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.41

Integrative molecular and functional profiling of ERBB2-amplified breast cancers identifies new genetic dependencies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.41

Functional viability profiles of breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.41

Rac1 contributes to trastuzumab resistance of breast cancer cells: Rac1 as a potential therapeutic target for the treatment of trastuzumab-resistant breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.41

Amplification of HER-2 in gastric carcinoma: association with Topoisomerase IIalpha gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.41

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.41

NIBP, a novel NIK and IKK(beta)-binding protein that enhances NF-(kappa)B activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.41

Predictors of resistance to preoperative trastuzumab and vinorelbine for HER2-positive early breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.41

Loss of phosphatase and tensin homolog or phosphoinositol-3 kinase activation and response to trastuzumab or lapatinib in human epidermal growth factor receptor 2-overexpressing locally advanced breast cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.41

Cyclin E amplification/overexpression is a mechanism of trastuzumab resistance in HER2+ breast cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.41

TRAPP I implicated in the specificity of tethering in ER-to-Golgi transport

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.41

Oncogenic Neu/ErbB-2 increases ets, AP-1, and NF-kappaB-dependent gene expression, and inhibiting ets activation blocks Neu-mediated cellular transformation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.41

Her2 activates NF-kappaB and induces invasion through the canonical pathway involving IKKalpha

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.41

Resistance to ErbB2 tyrosine kinase inhibitors in breast cancer is mediated by calcium-dependent activation of RelA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.41

The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.41

31 March 2020

Identifiers

DOI

10.1038/ONC.2013.41

1 reference

Dimensions Publication ID

3 August 2017

0 references

1 reference